Skip to main content

Table 2 Selected published studies on radiotherapy or chemotherapy in older patients with high.grade gliomas/glioblastomas

From: Radiation therapy for older patients with brain tumors

Authors

Type of study

Patients

Age years

RT dose Gy/fractions

CHT

Median PFS months

Median OS months

Bauman GS et al. [45]

Prospective

29

≥65

30/10

no

NA

6

Ford JM et al. [46]

Prospective

27

≥60

36/12

no

NA

4 (11% at 1 year)

Hoegler DB et al. [47]

Prospective

25a

≥70

37.5/15

no

NA

8

McAleese JJ et al. [48]

Prospective

30 29

65-70 ≥ 70

30/6 30/6

no no

NA NA

37% at 6 months 41% at 6 months

Chinot O et al. [49]

Prospective

32

≥70

no

TMZ°

5 (15% at 1 year)

6.4 (25% at 1 years)

Roa W et al. [50]

Randomized

51 49

≥60 ≥ 60

60/30 40/15

no no

NA NA

5.1 5.6

Keime-Guiber F et al. [44]

Randomized

39 39

≥70 ≥ 70

50/28 no

no no

3.6 1.5

7 4

Gallego Perez-Larraya et al. [51]

Prospective

70

≥70

no

TMZ°

4 (6.5% at at 1 year)

6 (11.4% at 1 year)

Malmstrom et al. [52]

Randomized

100 98 93

>60 > 60

60/30 34/10 no

no no TMZ°

NA NA NA

6 (17% at 1 year) 7.5 (23% at 1 year) 8.3 (27% at 1 year)

Wick et al. [53]

Randomized

178a 195a

>65 > 65

60/30 no

no TMZ °°

4.7 (9.3% at 1 year) 3.3 (12% at 1 year)

9.6 (37.4% at 1 year) 8.6 (34.4% at 1 year)

Roa et al. [54]

Randomized

48a 50a

≥65 ≥ 65

40/15 25/5

no no

4.2 4.2

7.9 6.4

  1. RT radiotherapy, CHT chemotherapy, OS overall survival, PFS progression-free survival, PCV procarbazine, CCNU Vincristine, TMZ Temozolomide, TMZ (200 mg/m2 on days 1–5) every 4 weeks, TMZ week-on/week-off (100 mg/m2 on days 1–7)
  2. aSeries include both elderly and frail patients, NA, not assessed